Spyre Therapeutics, Inc. Quarterly Debt-to-equity in % from Q3 2016 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Spyre Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q3 2016 to Q3 2024.
  • Spyre Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 29.9 %.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 29.9 +127 Sep 30, 2024
Q2 2024 60.7 +629 Jun 30, 2024
Q1 2024 -407 -444 -1213% Mar 31, 2024
Q4 2023 -175 -209 -619% Dec 31, 2023
Q3 2023 -97.3 -129 -408% Sep 30, 2023
Q2 2023 -568 -597 -2042% Jun 30, 2023
Q1 2023 36.6 +8.64 +30.9% Mar 31, 2023
Q4 2022 33.7 +5.55 +19.7% Dec 31, 2022
Q3 2022 31.6 +7.58 +31.5% Sep 30, 2022
Q2 2022 29.2 +8.24 +39.2% Jun 30, 2022
Q1 2022 27.9 +9.52 +51.7% Mar 31, 2022
Q4 2021 28.2 +10.4 +58.4% Dec 31, 2021
Q3 2021 24.1 +2.31 +10.6% Sep 30, 2021
Q2 2021 21 -4.69 -18.3% Jun 30, 2021
Q1 2021 18.4 -11.1 -37.6% Mar 31, 2021
Q4 2020 17.8 -2.88 -13.9% Dec 31, 2020
Q3 2020 21.7 +5.02 +30% Sep 30, 2020
Q2 2020 25.7 +11.9 +85.6% Jun 30, 2020
Q1 2020 29.5 +18.2 +160% Mar 31, 2020
Q4 2019 20.7 +8.57 +70.9% Dec 31, 2019
Q3 2019 16.7 +5.71 +51.9% Sep 30, 2019
Q2 2019 13.8 +3.59 +35% Jun 30, 2019
Q1 2019 11.4 +1.39 +14% Mar 31, 2019
Q4 2018 12.1 +3.51 +40.9% Dec 31, 2018
Q3 2018 11 +3.57 +48% Sep 30, 2018
Q2 2018 10.2 +3.64 +55.1% Jun 30, 2018
Q1 2018 9.95 +4.07 +69.2% Mar 31, 2018
Q4 2017 8.58 +0.07 +0.82% Dec 31, 2017
Q3 2017 7.44 -7.18 -49.1% Sep 30, 2017
Q2 2017 6.61 Jun 30, 2017
Q1 2017 5.88 Mar 31, 2017
Q4 2016 8.5 Dec 31, 2016
Q3 2016 14.6 Sep 30, 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.